




Patent Docket P1134R2C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Avi J. Ashkenazi et al. Serial No.: 10/688,132 Filed: October 17, 2003 For: DcR3 POLYPEPTIDE, A TNFR HOMOLOG	Group Art Unit: to be assigned Examiner: to be assigned CONFIRMATION NO: CUSTOMER NO: 09157 CERTIFICATE OF EXPRESS MAILING Express Mail Number: <u>EV 351 932 035 US</u> I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450". March 24, 2004  Diane L. Marschang
--	--

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Mail Stop MISSING PARTS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is responsive to the Notice to Comply with Requirements For Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated 1/28/2004.

Transmitted herewith are the following documents:

1. Amendment/Response;
2. Certificate re: Sequence Listing;
3. Sequence Listing (paper copy);
4. Letter and Request to Use Computer Readable Sequence Listing;
5. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures;
6. Request for a Corrected Filing Receipt;
7. Copy of Official Filing receipt hand-marked with corrections;

8. Return Postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630. A duplicate of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: March 24 2004

By: *Diane L. Marschang*
Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416

#151768

03-25-04



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/688,132	10/17/2003	Avi J. Ashkenazi	P1134R2C4

09157
 GENENTECH, INC.
 1 DNA WAY
 SOUTH SAN FRANCISCO, CA 94080



CONFIRMATION NO. 2023

FORMALITIES LETTER



OC000000011773715

Date Mailed: 01/28/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450

Alexandria VA 22313-1450


*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in black ink, appearing to read "Thuyh", is written over a horizontal line.

Customer Service Center


Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Patent Docket P1134R2C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Avi J. Ashkenazi et al. Serial No.: 10/688,132 Filed: October 17, 2003 For: DcR3 POLYPEPTIDE, A TNFR HOMOLOG	Group Art Unit: to be assigned Examiner: to be assigned Confirmation No: 2023 Customer No: 09157
<p align="center">CERTIFICATE OF EXPRESS MAILING</p> <p>Express Mail Number: EV 351 932 035 US</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450".</p> <p align="right">March <u>24</u>, 2004  Diane L. Marschang</p>	

CERTIFICATE RE: SEQUENCE LISTING
RESPONSE UNDER 37 CFR § 1.821(f) and (g)

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

I hereby state that the paper copy of the Sequence Listing submitted herewith is identical to the computer-readable diskette (as submitted in application Serial No. 09/894,924, filed June 28, 2001), and that the information recorded in computer readable form is identical to the enclosed paper copy of the sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,

GENENTECH, INC.

Date: March 24, 2004

By: 
Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416

#151760